Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for ...

To get a sense of who is truly in control of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), it is important to understand the ownership structure of the business. We can see that institutions own the ...

Equities research analysts at Leerink Partnrs cut their FY2026 earnings per share (EPS) estimates for Arrowhead ...

US Bancorp DE cut its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 14.0% during the ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released topline results from Part 2 of a Phase 1/2 study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce ...

In trading on Thursday, shares of Arrowhead Pharmaceuticals Inc (Symbol: ARWR) entered into oversold territory, hitting an RSI reading of 29.6, after changing hands as low as $14.87 per share.

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Century Therapeutics (IPSC – Research Report) ...

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), currently valued at $1.9 billion and trading near its 52-week low, announced the results of its 2025 Annual Meeting of Stockholders, which took place ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s ...

In January, the U.S. Food and Drug Administration accepted Arrowhead Pharmaceuticals’ New Drug Application for investigational plozasiran for familial chylomicronemia syndrome, a severe and rare ...